INSERM U1170, Equipe Labellisée Ligue Contre le Cancer, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94800 Villejuif, France; Gustave Roussy, 94800 Villejuif, France.
INSERM U1170, Equipe Labellisée Ligue Contre le Cancer, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94800 Villejuif, France; Université Paris Diderot, 75013 Paris, France.
Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.
Chimeric transcription factors are a hallmark of human leukemia, but the molecular mechanisms by which they block differentiation and promote aberrant self-renewal remain unclear. Here, we demonstrate that the ETO2-GLIS2 fusion oncoprotein, which is found in aggressive acute megakaryoblastic leukemia, confers megakaryocytic identity via the GLIS2 moiety while both ETO2 and GLIS2 domains are required to drive increased self-renewal properties. ETO2-GLIS2 directly binds DNA to control transcription of associated genes by upregulation of expression and interaction with the ETS-related ERG protein at enhancer elements. Importantly, specific interference with ETO2-GLIS2 oligomerization reverses the transcriptional activation at enhancers and promotes megakaryocytic differentiation, providing a relevant interface to target in this poor-prognosis pediatric leukemia.
嵌合转录因子是人类白血病的一个标志,但它们阻止分化并促进异常自我更新的分子机制仍不清楚。在这里,我们证明了在侵袭性急性巨核细胞白血病中发现的 ETO2-GLIS2 融合癌蛋白通过 GLIS2 部分赋予巨核细胞特性,而 ETO2 和 GLIS2 结构域都需要驱动增加的自我更新特性。ETO2-GLIS2 通过直接与 DNA 结合,通过上调表达和与增强子元件上的 ETS 相关 ERG 蛋白相互作用来控制相关基因的转录。重要的是,特异性干扰 ETO2-GLIS2 寡聚化可逆转增强子上的转录激活并促进巨核细胞分化,为这种预后不良的儿科白血病提供了一个相关的靶向界面。